<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321997</url>
  </required_header>
  <id_info>
    <org_study_id>EOP1003 and EOP1004</org_study_id>
    <nct_id>NCT00321997</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.</brief_title>
  <official_title>A PHASE II/III RANDOMIZED, DOUBLE-MASKED, CONTROLLED, DOSE-RANGING, MULTI-CENTER COMPARATIVE TRIAL, IN PARALLEL GROUPS, TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTIONS OF EYE001 (ANTI-VEGF PEGYLATED APTAMER) GIVEN EVERY 6 WEEKS FOR 54 WEEKS, IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyetech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eyetech Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the ability of different doses of pegaptanib sodium
      to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or
      impriving vision in patients with wet AMD when compared to placebo injections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date>October 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>540</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaptanib sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects of either gender, aged 50 years or greater. Subfoveal choroidal neovascularization
        (CNV) due to AMD. Best corrected visual acuity in the study eye between 20/40 and 20/320.

        Exclusion Criteria:

        Any prior subfoveal thermal laser therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2006</study_first_posted>
  <last_update_submitted>May 2, 2006</last_update_submitted>
  <last_update_submitted_qc>May 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2006</last_update_posted>
  <keyword>AMD</keyword>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Macugen</keyword>
  <keyword>pegaptanib sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

